Insurers Say Mallinckrodt Sales Strategy Cost Them $320M
By Rick Archer · November 12, 2021, 7:42 PM EST
A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login